If you’ve seen two Wegovy pill numbers and wondered which one to believe, here’s the short answer. Both come from Novo Nordisk, the maker, but they measure different things. The 6% figure is a three-month average for people who stayed on the pill the full three months, reported by Reuters on November 14, 2026. The 14% figure is the 64-week trial result, which counts everyone who started, whether or not they stayed on the drug. Because the length of time, the people and the counting all differ, the two numbers can’t be lined up side by side.
Disclosure: For clarity, several links on this page are affiliate links. If you buy through them, this publication may earn a commission. Your price is the same either way.
Is 6% at three months the same as the 14% trial result?
No. The real-world figure and the trial figure measure different things, so one can’t stand in for the other. The table below lists every pill figure in this story, with its time point, the people it covers, how it was counted and where it comes from.
| Figure | Time point | Population | Analysis type | Source |
|---|---|---|---|---|
| 6.2% average weight loss (6.3 kg, 13.9 lb) | 3 months | 5,872 adults on the Ro telehealth platform who had never taken a weight-loss drug and stayed on the pill for three months; start dates Jan. 5 to Feb. 7, 2026 | Completers (only people who stayed on the pill for three months) | Reuters, Nov. 14, 2026; figures provided by Novo |
| About 5.5% average weight loss | 12 weeks | Novo’s late-stage trial, as Reuters describes it | Trial result, as Reuters reports it | Reuters, Nov. 14, 2026, quoting Novo |
| 4.1% average weight loss (8.8 lb) | 3 months | 194 adults with overweight or obesity plus at least one complication, who switched from injectable semaglutide or tirzepatide to the pill | Retrospective; had to stay on the pill for three months with no gap over 30 days | Pharmaceutical Executive, Sept. 30, 2026, on Novo’s OCTANE analysis |
| 13.6% vs 2.4% with placebo | 64 weeks | 307 adults with obesity, or overweight plus a weight-related condition; type 2 diabetes excluded | Treatment-policy (everyone who started, regardless of whether they stayed on treatment) | OASIS 4 trial, sponsored by Novo Nordisk; Novo release dated Dec. 22, 2025 |
| 16.6% vs 2.7% with placebo | 64 weeks | The same 307 adults | On-treatment (an idealized estimate in which everyone stayed on treatment and used no other weight-loss therapy) | OASIS 4, as reported by Healio, Dec. 23, 2025 |
Why 6% at three months and 14% at 64 weeks don’t line up
- Length. One figure is three months. The other is 64 weeks. They sit at different points on the timeline.
- Who gets counted. The 6.2% counts only people who stayed on the pill for three months. The 13.6% counts everyone who started, including people who stopped. The 16.6% counts only if everyone stayed on treatment.
- Who the people were. The real-world group had never taken a weight-loss drug before. The OASIS 4 trial enrolled 307 adults with obesity or overweight plus a weight-related condition, and excluded adults with type 2 diabetes.
- Comparison. Reuters’ report describes no placebo group for the 6.2%. OASIS 4 was randomized, double-blind and placebo-controlled, and the placebo group averaged 2.4% (13.6% figure) and 2.7% (16.6% figure).
Novo’s chief scientific officer, Martin Holst Lange, told Reuters the real-world result broadly matched the trial, which he called encouraging. That is Novo’s own view, and Reuters reports it as such.
How much weight could I lose on Wegovy pill in 3 months?
For people who stayed on the pill for three months, Reuters reports an average loss of 6.2% of body weight, or 6.3 kg (13.9 lb), from a starting average of 103.0 kg (227 lb). About three-fifths of that group lost at least 5%, and roughly one in six lost at least 10%.
In Novo’s 64-week trial, 76.3% of people on the pill lost 5% or more, against 31.3% on placebo, according to the Novo pill page. Novo’s pill page also says that people respond to the medication differently and gives no set time to see results. It adds that “individual results may vary.”
The pill is meant to be used with a reduced-calorie diet and more physical activity. Novo’s page advises you to “talk to your healthcare professional about a goal weight that is healthy and realistic for you.”
What happened with the November real-world report
Reuters reported on November 14, 2026 that Novo’s real-world data showed the 6.2% average, with the data set to be presented at the ObesityWeek conference. The group was 5,872 adults who started on the Ro telehealth platform between January 5 and February 7, 2026. Reuters says the figures were provided by Novo, and its report does not describe the study design or name a funder.
Novo had separately released its OCTANE data on September 30, 2026. That analysis covered 194 adults who switched from injectable semaglutide or tirzepatide and reported a 4.1% average loss at three months.
Key dates
- Dec. 22, 2025: Novo’s release announces that FDA approved the once-daily Wegovy pill. Novo calls it the first oral GLP-1 for obesity in the US.
- January 2026: The pill launches in the US. The start window for both real-world groups opens on January 5, 2026.
- Sept. 30, 2026: The OCTANE analysis is presented at the EASD meeting in Milan.
- Nov. 14, 2026: Reuters reports the 6.2% three-month figure.
Who the pill is for, and who it isn’t
Novo’s release says the pill is approved for adults with obesity, or with overweight plus at least one weight-related problem, alongside diet and activity. Safety and effectiveness are not established under age 18, according to the same release.
Novo’s release lists several reasons the pill is contraindicated: a personal or family history of medullary thyroid carcinoma or MEN 2, or a prior serious allergy to semaglutide. It also says to stop the pill two months before a planned pregnancy and that it is not recommended while breastfeeding.
The OASIS 4 trial excluded adults with type 2 diabetes. Novo’s pill page says the pill has not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight.
Common mix-ups
- 6.2% vs 4.1%. These are different groups. The 6.2% covers people who had never taken a weight-loss drug and started the pill. The 4.1% covers people who switched from injections. Neither number compares the pill with injections directly.
- 14% vs 16.6%. Both come from OASIS 4 at 64 weeks. The 14% (13.6% in the trial data) counts everyone who started. The 16.6% assumes everyone stayed on treatment. Reuters’ “about 14%” matches the 13.6% figure.
- The weekly injection’s real-world numbers. A WeGoTogether real-world study followed people on the weekly semaglutide injection, a retrospective cohort in which weights were self-reported. It reports a 13.4% average loss at six months. That is the injection, not the pill, so the figure is a different product and a different data source.
- The pill’s medicine guide. The NIDDK’s prescription medicines page for weight management was last reviewed in June 2024 and lists only injectable semaglutide, so it doesn’t cover the pill.
- Ozempic and Wegovy. If the two names are getting mixed up, the what is the difference between ozempic and wegovy guide walks through them.
Side effects and how to take the pill
Novo’s release lists nausea, diarrhea and vomiting as the common reactions. It also lists constipation, abdominal pain, headache, fatigue, dizziness, bloating, belching, gas and heartburn.
Healio reports that most adverse events were gastrointestinal, such as nausea, vomiting and constipation. Healio also reports the pill must be taken on an empty stomach, with eating delayed about 30 minutes.
Questions to settle your next step
- Ask your prescriber what weight-loss goal is healthy and realistic for you, and whether the 6% or the 14% figure fits your situation.
- Ask your prescriber whether the pill suits you, given the contraindications and warnings in the full prescribing information.
- Ask a pharmacist to walk you through taking it on an empty stomach and the wait before eating.
- Check today’s price with your pharmacy or prescriber. Novo’s Dec. 22, 2025 release gave $149 a month for the 1.5 mg commercial starting dose, with savings offers, as a company statement.
- For a primer on comparing study numbers yourself, read how to read weight loss research.
By Sense and Evidence Health Research Team